Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2014, 23(5):348-352

Natriuretic peptides and heart failure - useful in early diagnosis

Murín J1, Rajecová O2, Daňová K3, Pivovarníková H4, Margóczy R5, Pernický M1, Kamenský G6
1 I. interná klinika LFUK a UN Bratislava
2 Roche Slovensko, s.r.o., Bratislava
3 OLM, Národný ústav srdcových a cievnych chorôb a.s., Bratislava
4 Synlabu slovakia s.r.o., Prešov
5 Stredoslovenský ústav srdcových a cievnych chorôb a.s., Banská Bystrica
6 V. interná klinika LFUK a UN Bratislava, Slovenská republika

Chronic heart failure is today an epidemic disease and every rehospitalization of a patient increases his mortality and morbidity. A bad prognosis of heart failure can be influenced by an early diagnosis and treatment of the disease. Part of heart failure diagnostics is not only clinical examination of the patient but also investigation of his serum NT-proBNP biomarker. The value of serum NT-proBNP at admission not only states the presence of heart failure but can also tell us the prognosis of the patient. The value at discharge can show us how successful we were in the hospital treatment, but can also tell us the further prognostic risk of the patient. We try to bring here useful, practical information about the serum NT-proBNP biomarker in heart failure, with cut-off values for diagnosis of acute and chronic heart failure included. Early and intensive heart failure treatment, guided by monitoring o serum NT-proBNP parameters, can improve long-term prognosis of heart failure.

Keywords: heart failure; acute heart failure; diagnosis of heart failure; serum NT-proBNP -prognosis

Published: May 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Murín J, Rajecová O, Daňová K, Pivovarníková H, Margóczy R, Pernický M, Kamenský G. Natriuretic peptides and heart failure - useful in early diagnosis. Cardiology Letters. 2014;23(5):348-352.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. doi:10.1016/j.ejheart.2008.08.005
    2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and stroke Statistics 2011 Update: a report from AHA. Circulation 2011;123:e18-e209.
    3. Bishu K, Deswal A, Chen H, et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J 2012;164:763-770. Go to original source...
    4. Lee CY, Burnet JR. Natriuretic peptides and therapeutic applica­ tions. Heart Fail Rev 2007;12:131-142. Go to original source...
    5. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute de­ stabilized heart failure:an international pooled analysis of 1256 patients: the International Collaborative of NT/proBNP Study. Eur Heart J 2006;27:330-337. Go to original source...
    6. Troughton R, Felker M, Januzzi JL. Natriuretic peptide-guided heart failure management. Eur Heart J 2014;35:16-24. Go to original source...
    7. Thygessen L, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care. A postion statement from the Study Group on Biomarkers in Cardiology of the ESC WG on Acute Cardiac Care. Eur Heart J 2012;33:20012006. Go to original source...
    8. McMurray JJ,Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33:1787-1847. Go to original source...
    9. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the management of heart failure: A report of the ACC Foundation and AHA Task Force on Practice Guidelines. Circulation 2013;128:1810-1852. Go to original source...
    10. Levis ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328. Go to original source...
    11. Lee CY, Burnett JC jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007;12:131-142. Go to original source...
    12. Rubattu S, Volpe M. The atrial natriuretic peptide: a changing view. J Hypertens 2001;19:1923-1931. Go to original source...
    13. Tonne JM, Campbell JM, Cataliotti A, et al. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem 2011;57:864-873. Go to original source...
    14. Chauhan SD, Hobbs AJ, Ahluwalia A. C-type natriuretic peptide: new candidate for endothelium-derived hyperpolarizing factor. Int J Biochem Cell Biol 2004;36:1878-1881. Go to original source...
    15. Focaccio A, Volpe M, Ambrosio G, et al. Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation 1993;87:192-198. Go to original source...
    16. Bruneau BG, de Bold AJ. Selective changes in natriuretic peptide and early response gene expression in isolated rat atria fo­ llowing stimulation by stretch or endothelin-1. Cardiovasc Res 1994;28:1519-1525. Go to original source...
    17. Rubattu S, Sciarretta S, Valenti V, et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use and implication in cardiovscular diseases. Am Hypertens 2008;21:733-741. Go to original source...
    18. Bordicchia M, Liu D, Amri A-Z et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012;122:10221036. Go to original source...
    19. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-585. Go to original source...
    20. Lassus J, Gayat E, Mueller C, et al. for the Great Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013;168:2186-2194. Go to original source...
    21. Boerrigter G, Costello-Boerrigter LC, Burnett JC jr. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin 2009;5:501-514. Go to original source...
    22. van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61:14981506. Go to original source...
    23. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013;310:66-74. Go to original source...
    24. Eurlings LWM, van Pol PEJ, Kok WE, et al. Management of chronic heart failure guided by individual N-Terminal Pro-B-Type natriuretic peptide targets (PRIMA study). J Am Coll Cardiol 2010;56:2090-2100. Go to original source...
    25. Bhardwaj A, Januzzi JL. Natriuretic peptide-guided management of acutely destabilized heart failure. Rationale and treatment algorithm. Critical Pathways Cardiol 2009;8:146-150. Go to original source...
    26. Motiwala SR, Januzzi JL. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. Clin Pharm Therap 2013;93:57-67. Go to original source...
    27. Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart faillure: a metaanalysis of 2 686 patients in 12 randomized trials PLoS ONE 2013;8:e58287. Go to original source...
    28. Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006;175:611-617. Go to original source...
    29. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004;6:355-358. Go to original source...
    30. Mentz RJ, Felker GM. Natriuretic peptide-guided therapy for heart failure. Circ J 2011;75:2031-2037. Go to original source...
    31. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) 2005;108:23-36. Go to original source...
    32. Pereira M, Azevedo A, Severo M, Barros H. Long-term stability of endogenous B-type natriuretic peptide after storage at -20 degrees C or -80 degrees C. Clin Chem Lab Med 2008;46:11711174. Go to original source...
    33. Chien TI, Chen HH, and Kao JT. Comparison of Abbott Axsym and Roche Elecsys 2010 for measurement of BNP and NTproBNP. Clin Chim Acta 2006;369:95-99. Go to original source...
    34. Mueller T, Gegenhuber A, Dieplinger B, et al. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942-944. Go to original source...
    35. De Lemos JA, McGuire DK, Khera A., Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J 2009;157:746-753. Go to original source...
    36. O'Donoghue M, Chen A, Baggish AL, et al. The Effects of Ejection Fraction on N-Terminal ProBNP and BNP Levels in Patients With Acute CHF: Analysis From the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Card Failur 2005;11:S9-S14. Go to original source...
    37. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data. Clin Chem 2006;52:1528-1538. Go to original source...
    38. Januzzi JL, van Kimmenade R, Lainchbury, et al. NT-proBNP test­ ing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients (International Collaborative of NT-proBNP Study). Eur Heart J 2006;27:330-337. Go to original source...
    39. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012;33:2001-2006. Go to original source...
    40. Gustafsson F, Badskjaer J, Hansen FS, et al. Value of N-Terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 2003;3:141-146. Go to original source...
    41. Januzzi JL, Rehman SU. Use of amino-terminal Pro-B Type Natri­ uretic Peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58:1881-1889 Go to original source...
    42. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008;52:997-1003. Go to original source...

    Return to the content